235 related articles for article (PubMed ID: 25749587)
1. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
[TBL] [Abstract][Full Text] [Related]
2. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
3. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
[TBL] [Abstract][Full Text] [Related]
4. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
[TBL] [Abstract][Full Text] [Related]
6. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Skaltsa K; Domènech B; Lomeña F; Pons F
Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):291-8. PubMed ID: 22695339
[TBL] [Abstract][Full Text] [Related]
7. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
9. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
[TBL] [Abstract][Full Text] [Related]
12. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
Hawkins DS; Schuetze SM; Butrynski JE; Rajendran JG; Vernon CB; Conrad EU; Eary JF
J Clin Oncol; 2005 Dec; 23(34):8828-34. PubMed ID: 16314643
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
14. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
[TBL] [Abstract][Full Text] [Related]
16. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
[TBL] [Abstract][Full Text] [Related]
19. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
20. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
